Aardvark Therapeutics (AARD) Liabilities and Shareholders Equity (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $98.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 37.21% year-over-year to $98.6 million; the trailing twelve-month figure through Mar 2026 stood at $496.5 million (up 111.69% YoY), and the FY2025 full-year result was $117.2 million, up 51.19% from the prior year.
• Liabilities and Shareholders Equity eased to $98.6 million in Q1 2026, from $117.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $157.0 million in Q1 2025 to a low of $77.5 million in Q4 2024.
• A 3-year average of $121.8 million and a median of $125.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 51.19% in 2025 and sank 37.21% in 2026, its largest moves.
• Tracing AARD's Liabilities and Shareholders Equity over 3 years: stood at $77.5 million in 2024, then soared by 51.19% to $117.2 million in 2025, then decreased by 15.87% to $98.6 million in 2026.
• Business Quant data shows AARD's Liabilities and Shareholders Equity at $98.6 million in Q1 2026, $117.2 million in Q4 2025, and $133.2 million in Q3 2025.